A Single CD4 Test with 250 Cells/Mm3 Threshold Predicts Viral Suppression in HIV-Infected Adults Failing First-Line Therapy by Clinical Criteria
Authors:
- Charles F. GilksCGCharles F. Gilks
- A. Sarah WalkerAWA. Sarah Walker
- Ruth L. GoodallRGRuth L. Goodall
- Heiner GrosskurthHGHeiner Grosskurth
- Diana M. GibbDGDiana M. Gibb
- on behalf of the DART Virology Group and Trial TeamOTon behalf of the DART Virology Group and Trial Team
Open Access
- 21 February 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (2) , e57580
Abstract
In low-income countries, viral load (VL) monitoring of antiretroviral therapy (ART) is rarely available in the public sector for HIV-infected adults or children. Using clinical failure alone to identify first-line ART failure and trigger regimen switch may result in unnecessary use of costly second-line therapy. Our objective was to identify CD4 threshold values to confirm clinically-determined ART failure when VL is unavailable. 3316 HIV-infected Ugandan/Zimbabwean adults were randomised to first-line ART with Clinically-Driven (CDM, CD4s measured but blinded) or routine Laboratory and Clinical Monitoring (LCM, 12-weekly CD4s) in the DART trial. CD4 at switch and ART failure criteria (new/recurrent WHO 4, single/multiple WHO 3 event; LCM: CD43) were reviewed in 361 LCM, 314 CDM participants who switched over median 5 years follow-up. Retrospective VLs were available in 368 (55%) participants. Overall, 265/361 (73%) LCM participants failed with CD43; only 7 (2%) switched with CD4≥250 cells/mm3, four switches triggered by WHO events. Without CD4 monitoring, 207/314 (66%) CDM participants failed with WHO 4 events, and 77(25%)/30(10%) with single/multiple WHO 3 events. Failure/switching with single WHO 3 events was more likely with CD4≥250 cells/mm3 (28/77; 36%) (p = 0.0002). CD4 monitoring reduced switching with viral suppression: 23/187 (12%) LCM versus 49/181 (27%) CDM had VL3 only 11/133 (8%) had VL3 (p3 for clinically-monitored patients failing first-line could identify ∼80% with VL<400 copies/ml, who are unlikely to benefit from second-line. Targeting CD4s to single WHO stage 3 ‘clinical failures’ would particularly avoid premature, costly switch to second-line ART.Keywords
This publication has 19 references indexed in Scilit:
- Lopinavir/Ritonavir Monotherapy after 24 Weeks of Second-Line Antiretroviral Therapy in Africa: A Randomized Controlled Trial (Sara)Antiviral Therapy, 2012
- Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trialThe Lancet, 2010
- Viremia, Resuppression, and Time to Resistance in Human Immunodeficiency Virus (HIV) Subtype C during First‐Line Antiretroviral Therapy in South AfricaClinical Infectious Diseases, 2009
- Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteriaTropical Medicine & International Health, 2009
- Misclassification of First‐Line Antiretroviral Treatment Failure Based on Immunological Monitoring of HIV Infection in Resource‐Limited SettingsClinical Infectious Diseases, 2009
- Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in UgandaAIDS, 2009
- CD4+ T-Cell Count Monitoring Does Not Accurately Identify HIV-Infected Adults With Virologic Failure Receiving Antiretroviral TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/μlAIDS, 2008
- Twenty‐four‐week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first‐line antiretroviral therapy: a randomized double‐blind trial (NORA)*Tropical Medicine & International Health, 2008
- The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settingsThe Lancet, 2006